Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Roundhill GLP-1 & Weight Loss ETF (OZEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OZEM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit -4.77% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Volume (30-day avg) 11308 | Beta - | 52 Weeks Range 23.09 - 29.15 | Updated Date 04/1/2025 |
52 Weeks Range 23.09 - 29.15 | Updated Date 04/1/2025 |
Upturn AI SWOT
Roundhill GLP-1 & Weight Loss ETF
ETF Overview
Overview
The Roundhill GLP-1 & Weight Loss ETF (OZEM) seeks to provide investment results that correspond generally to the total return performance of the EQM GLP-1 & Weight Loss Index. It focuses on companies involved in the development and production of glucagon-like peptide-1 (GLP-1) receptor agonists and other weight loss therapeutics.
Reputation and Reliability
Roundhill Investments is an innovative ETF provider known for thematic ETFs focused on emerging and disruptive technologies.
Management Expertise
Roundhill's management team has experience in ETF creation, distribution, and thematic investing.
Investment Objective
Goal
To track the performance of the EQM GLP-1 & Weight Loss Index before fees and expenses.
Investment Approach and Strategy
Strategy: The ETF employs a replication strategy, meaning it aims to hold all or substantially all of the securities in the underlying index.
Composition The ETF holds stocks of companies involved in the GLP-1 and weight loss industry, including pharmaceutical companies, biotech firms, and medical device manufacturers.
Market Position
Market Share: OZEM is a relatively new entrant in a developing thematic ETF space, and its market share is evolving.
Total Net Assets (AUM): 94900000
Competitors
Key Competitors
Competitive Landscape
Since the GLP-1 and weight loss ETF market is new, the competitive landscape is still forming. OZEM's success will depend on its ability to attract assets and maintain a low expense ratio relative to other thematic ETFs with similar exposure. Direct competitors are nascent or may not exist in a directly comparable format. As the market matures, other ETFs with exposure to the pharmaceutical and biotechnology sectors may indirectly compete for investor capital.
Financial Performance
Historical Performance: Historical performance data is limited due to the ETF's recent inception.
Benchmark Comparison: The ETF's performance should be compared to the EQM GLP-1 & Weight Loss Index.
Expense Ratio: 0.59
Liquidity
Average Trading Volume
The ETF's average trading volume can vary, but is generally sufficient for most investors.
Bid-Ask Spread
The bid-ask spread is usually competitive, reflecting the ETF's liquidity and market demand.
Market Dynamics
Market Environment Factors
The ETF is influenced by factors such as pharmaceutical industry trends, FDA approvals of weight loss drugs, clinical trial results, and overall market sentiment towards healthcare and biotechnology.
Growth Trajectory
The growth trajectory depends on the increasing adoption of GLP-1 therapies, new drug developments, and the expanding market for weight loss solutions. Potential changes may include adjustments to the underlying index and holdings based on industry developments.
Moat and Competitive Advantages
Competitive Edge
OZEM provides targeted exposure to a potentially high-growth segment of the pharmaceutical industry, offering investors a way to capitalize on the increasing demand for GLP-1 therapies. The ETF's focused investment strategy differentiates it from broader healthcare ETFs. Its success is tied to the growing awareness and adoption of these therapies. Roundhill's expertise in thematic ETFs can also contribute to its success, attracting investors interested in innovative healthcare solutions.
Risk Analysis
Volatility
The ETF may experience volatility due to the inherent risks associated with the pharmaceutical and biotechnology sectors, including regulatory hurdles, clinical trial failures, and market competition.
Market Risk
Specific risks include concentration risk (exposure to a limited number of companies), regulatory risk (related to FDA approvals), and clinical trial risk (potential for drug failures).
Investor Profile
Ideal Investor Profile
The ideal investor is someone seeking targeted exposure to the GLP-1 and weight loss market, with a higher risk tolerance and a long-term investment horizon.
Market Risk
The ETF may be suitable for long-term investors seeking growth potential in a specific thematic area, but is not appropriate for risk-averse investors or those seeking stable income.
Summary
The Roundhill GLP-1 & Weight Loss ETF (OZEM) offers investors focused exposure to companies involved in the burgeoning GLP-1 and weight loss therapeutics market. The ETF's performance is directly tied to the success and adoption of these therapies, making it a potentially high-growth but also volatile investment. Investors should be aware of the concentration risk and regulatory challenges associated with the pharmaceutical industry. OZEM is suitable for investors with a long-term horizon and a higher risk tolerance seeking to capitalize on this innovative healthcare area.
Similar Companies
IBB
iShares Biotechnology ETF
IBB
iShares Biotechnology ETF
PJP
Invesco Dynamic Pharmaceuticals ETF
PJP
Invesco Dynamic Pharmaceuticals ETF
XBI
SPDR® S&P Biotech ETF
XBI
SPDR® S&P Biotech ETF
XLV
Health Care Select Sector SPDR® Fund
XLV
Health Care Select Sector SPDR® Fund
Sources and Disclaimers
Data Sources:
- Roundhill Investments Website
- EQM Indexes
- SEC Filings
Disclaimers:
The data provided is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Roundhill GLP-1 & Weight Loss ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.